Popular Posts: 13 “Triple A” Stocks to BuyHottest Technology Stocks Now – ASX DDD HIMX CDNS9 Oil and Gas Stocks to Buy Now Recent Posts: 3 Chemicals Stocks to Buy Now 7 “Triple F” Stocks to Sell 3 Chemicals Stocks to Sell Now View All Posts This week, four pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
NuPathe Inc.’s () grade is moving up to a B (“buy”) this week from last week’s C (“hold”). NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. .
Watson Pharmaceuticals () is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. .
Impax Laboratories, Inc. () shows solid improvement this week. The company’s rating rises from a C to a B. Impax Laboratories develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. .
Mylan () gets a higher grade this week, advancing from a B last week to an A. Mylan is a global generic and specialty pharmaceuticals company. .
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
No comments:
Post a Comment